Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cipla’s Proventil Generic Gnaws At US Market

Executive Summary

Cipla’s generic of Merck & Co’s Proventil makes significant inroads in the US, with the Indian company confident that it has both a strong cost position and large capacity to take on competition. Pricing in the segment currently remains ‘respectable’.

You may also be interested in...



Perrigo’s Loss Is Lupin’s Gain On Albuterol

Having gained from Perrigo’s US withdrawal of generic ProAir (albuterol sulphate), Lupin plans to ramp up capacity by its financial fourth quarter as demand is seen rising on account of flu and COVID-19 cases in the US. Meanwhile, FDA observations at its Somerset facility provide a dampener.

Perrigo’s Loss Is Lupin’s Gain

Having gained from Perrigo’s withdrawal of generic ProAir (albuterol sulphate), Lupin plans to ramp up capacity by Q4 as demand is seen rising on account of flu and COVID-19 cases in the US. Meanwhile, FDA observations at its Somerset facility are a dampener

How Cipla Is Aligning Manufacturing Amid The Pandemic

Cipla senior management executive tells Scrip how the company is calibrating manufacturing as part of a wider business “reimagination” and accelerated digital adoption across its operations.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC142754

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel